CARLSBAD, Calif., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that it has amended and restated its loan agreement with Silicon Valley Bank that provides for a $32 million working capital revolving line of credit.
The new credit facility is based on the Company's working capital balances for eligible accounts receivable and inventory. The maturity date of the credit facility is October 2013. The credit facility provides a significant reduction in interest expense and terminates the principal amortization payments that existed in the prior credit facility.
The proceeds of the new credit facility shall primarily be used to pay off the Company's existing credit facilities with Silicon Valley Bank and Oxford Finance Corporation."We are pleased to extend our credit and commercial banking relationship with Silicon Valley Bank. The new facility provides a significant reduction in our current debt service costs, which allows us to have more flexibility in the funding of our operations," said Dirk Kuyper, the Company's President and Chief Executive Officer. Michael White, Senior Relationship Manager, Life Sciences, Silicon Valley Bank added, "We value our relationship with Alphatec Spine and are pleased to continue providing them with the financing and banking services they need to grow their business both here in the U.S. and internationally." A copy of the credit agreement referenced in this press release will be filed with the SEC by the Company and the foregoing description is subject to the actual terms of the agreement. About Alphatec Spine Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its subsidiary, Scient'x S.A., via a direct salesforce in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa, South America and Latin America. In Asia and Australia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc, and through Scient'x's distributors in China, Korea and Australia.